Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer

Conclusions
CD4+CD25+FOXP3+ and CD8+CD28– Treg percentages were higher in patients with NSCLC than control subjects, and increased in line with tumour progression. Percentages of CD4+CD25+FOXP3+ and CD8+CD28– Tregs were significantly reduced following gemcitabine plus cisplatin chemotherapy.

Source: Journal of International Medical Research - March 16, 2015 Category: Research Authors: Chen, C., Chen, Z., Chen, D., Zhang, B., Wang, Z., Le, H. Tags: Research Reports Source Type: research